Last reviewed · How we verify

NCT07292766

Metabolomic Profiling of Patients With Traumatic Brain Injury

Recruiting now Last updated 18 December 2025
What this trial tests

trial in Traumatic Brain Injury in 60 participants. Currently enrolling.

Timeline
1 February 2024
Primary endpoint
1 December 2025
1 February 2026

Quick facts

Lead sponsorDr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment60
Start date1 February 2024
Primary completion1 December 2025
Estimated completion1 February 2026
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Who can join

Adults 18 to 65, any sex, with Traumatic Brain Injury or Traumatic Brain Injury (TBI) Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Traumatic Brain Injury (TBI) is a significant cause of mortality and morbidity worldwide. However, the literature on determining its severity and predicting prognosis is insufficient. This study aimed to examine the differences in metabolite levels between trauma patients with severe TBI and orthopedic trauma patients without brain injury.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Traumatic Brain Injury

Currently open trials in the same condition.

Other Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07292766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing